AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
04 January 2012
Eleanor Malone
Please Login to read the full article.
04 January 2012
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- Aveo raises another $100M, as tivozanib goes head-to-head with Nexavar in RCC
- AVEO's unconvincing Phase II ficlatuzumab data point to need for further studies
- EMA accepts Pfizer's axitinib for review in renal cell carcinoma
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
